Is Viela Bio Inc (VIE) Stock a Good Buy on Tuesday?

Tuesday, June 2, 2020 11:12 AM | InvestorsObserver Analysts

Overall market sentiment has been down on Viela Bio Inc (VIE) stock lately. VIE receives a Bearish rating from InvestorsObserver's Stock Sentiment Indicator.

Sentiment Score - ,bearish
Viela Bio Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on VIE!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.

Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.

InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.

The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With VIE Stock Today?

Viela Bio Inc (VIE) stock has risen 2.57% while the S&P 500 is lower by -0.02% as of 11:12 AM on Tuesday, Jun 2. VIE has risen $1.24 from the previous closing price of $48.17 on volume of 121,042 shares. Over the past year the S&P 500 has gained 4.96% while VIE has risen 111.06%. VIE lost -$2.55 per share in the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Viela Bio Inc click here.

More About Viela Bio Inc

Viela Bio Inc is a clinical-stage biotechnology company engaged in developing and commercializing transformative treatments for severe inflammation and autoimmune diseases. Its product inebilizumab, is a humanized monoclonal antibody, designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

40% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 57% with annual

InvestorsObserver Premium

$ 20.75 $ 12.45 /month
$249 $149.40 billed annually

You May Also Like

Related Articles

Related Companies